SynthesisAnnals of surgical oncology2026
Oncologic Outcomes of Sentinel Lymph Node Biopsy Versus Targeted Axillary Dissection for Node-Positive Breast Cancer Patients After Neoadjuvant Chemotherapy: A Systematic Review and Meta-Analysis.
Synthesis in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Targeted axillary dissection versus sentinel lymph node biopsy after neoadjuvant chemotherapy: are we underestimating the clinical significance of staging accuracy?Translational breast cancer research : a journal focusing on translational research in breast cancer · 2026Article
Corrections and comments
- Commented on by
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIncreasing evidence supports the oncologic safety of de-escalating axillary surgery after neoadjuvant chemotherapy (NAC). For patients with node-positive (cN+) breast cancer initially whose axilla is downstaged after NAC (ycN0), sentinel lymph node biopsy (SLNB) or targeted axillary dissection (TAD) is acceptable, with controversy surrounding the optimal technique. This study aimed to assess the oncologic and survival outcomes of SLNB versus TAD for cN+ patients who are converted to ycN0 after NAC.
methodsA systematic literature search of relevant databases was conducted. A meta-analysis using the Mantel-Haenszel method was performed to calculate odds ratios (ORs) of axillary recurrence (AR), 3-year disease-free survival (DFS), and overall survival (OS) for SLNB compared with TAD.
resultsFive studies involving 2849 patients (SLNB, n = 1842; TAD, n = 1007) were included. The rate of AR did not differ between SLNB and TAD (OR, 1.23; 95% confidence interval [CI], 0.33-4.65; p = 0.76). Patients who underwent SLNB had a modestly reduced 3-year DFS (OR, 1.53; 95% CI, 1.11-2.12; p = 0.01) compared with those undergoing TAD. There was no difference in 3-year OS between SLNB and TAD (OR, 2.12; 95% CI, 0.59-7.55; p = 0.25).
conclusionsAccurate axillary staging after NAC is important to guide adjuvant therapies. The rate of AR is very low and equivalent after SLNB or TAD for cN+ breast cancer patients who become ycN0 after NAC. Further studies are warranted to confirm whether TAD provides a clear survival advantage compared with SLNB in long-term follow-up evaluation.
Indexed as
Identifiers
41545613What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.